1 Yale School of Medicine, New Haven, CT [email protected]
2 Genentech, South San Francisco, CA
3 Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN
Dr. Herbst reports having received advisory board fees from Cybrexa. An updated disclosure form has been posted with the full text of the original article at NEJM.org. Since publication of the article, Dr. Herbst reports having received consulting fees from Oncternal Therapeutics. Since publication of the article, Dr. Spigel reports consulting fees paid to his institution from Amgen, Exelixis, Intellisphere, Ipsen Biopharmaceuticals, Jazz Pharmaceuticals, Mirati Therapeutics, and Puma Biotechnology, and research grants to his institution from Agios, Lilly, GlaxoSmithKline, Tesaro, Cyteir Therapeutics, and Apollomics. No further potential conflict of interest relevant to this letter was reported.
